Daiichi Sankyo to Present Findings From New Subgroup Analyses of Once-Daily LIXIANA®▼ (edoxaban) in NVAF and VTE at ACC'

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 17,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to its strong portfolio of medicines for hypertension, dyslipidemia, bacterial infections, and thrombotic disorders, the Group's research and development is focused on bringing forth novel therapies in cardiovascular-metabolic diseases, pain management, and oncology, including biologics. For more information, please visit: http://www.daiichisankyo.com .

Forward-looking statements 

This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO Co., Ltd. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO Co., Ltd. assume no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.

References 

1) Giugliano R, et al. Edoxaban versus warfarin in patients with atrial fibrillation.

N Engl J Med. 2013;369(22):2093-2104.

2) Büller H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous

thromboembolism. N Engl J Med. 2013;369(15):1406-1415.

3) National Heart, Lung and Blood Institute - What is Atrial Fibrillation. Available at:

http://www.nhlbi.nih.gov/health/dci/Dise... . [Last

accessed: March 2016].

4) Iqbal MB, et al. Recent developments in atrial fibrillation. BMJ. 2005;330(7485)

:238-43.

5) Camm A, et al. Guidelines for the management of atrial fibrillation: the Task Force

for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

Eur Heart J. 2010;31(19):2369-2429.

6) Krijthe BP, et al. Projections on the number of individuals with atrial fibrillation

in the European Union, from 2000 to 2060. Eur Heart J. 2013;34(35):2746-2751.

7) Ball J, et al. Atrial fibrillation: Profile and burden of an evolving epidemic in the

21st century. Int J Card. 2013;167:1807-1824.

8) Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE) - Blood Clot Forming in a Vein.

Centers for Disease Control and Prevention. Available at:

http://www.cdc.gov/ncbddd/dvt/facts.html... . [Last accessed: March 2016].

9) Van Beek E, et al. Deep vein thrombosis and pulmonary embolism. New York: John Wiley &

Sons, 2009. Print.

10) Cohen A, et al. Venous thromboembolism (VTE) in Europe. Thromb Haemost. 2007;98(4)

:756-764.

11) Kearon C. Natural history of venous thromboembolism. Circulation. 2003;107(23 suppl 1)

:I-22-30.

Contact 

Kimberly Wix (U.S) 

Daiichi Sankyo, Inc. 

Senior Director, Public Affairs 

+1-973-944-2338

Lydia Worms (Europe) 

Daiichi Sankyo Europe GmbH 

Edoxaban Communications & Product PR Europe 

+49(89)7808751 

EDX/16/0070 

Date of prep: March 2016